Amneal Pharmaceuticals, Inc. Class A (AMRX)

Amneal Pharmaceuticals' stock has experienced significant growth, rising 85.0% over the past year, outperforming the US Pharmaceuticals industry and the broader US Market. It reached a new 52-week high of $13.84 in January 2026. Amneal reported strong financial results, with Q3 2025 net revenue of $785 million, a 12% increase year-over-year, and consistently beat analysts' EPS expectations. S&P Global Ratings revised Amneal's outlook to positive from stable, driven by strong financial results and the company's commitment to reducing leverage. The stock has received a consensus rating of "Moderate Buy" from analysts, with an average price target of $13.80. There has been significant open-market selling from key executives, with insiders selling approximately $70.0 million worth of shares over the last year, although they also bought or received $18.7 million worth of shares.

Amneal Pharmaceuticals has indicated that the seasonal impact of certain products may affect quarterly comparisons within any fiscal year. The company is also involved in addressing future clinical needs for conditions like Parkinson's disease and migraines, indicating a growing long-term demand for treatments in these areas.

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing, manufacturing, and distributing generic and specialty pharmaceutical products. The company operates across three main segments: Affordable Medicines, Specialty, and AvKARE. Amneal operates within the pharmaceutical sector. The Affordable Medicines segment focuses on generics, injectables, and biosimilars, offering a diverse portfolio of approximately 250 products. The Specialty Segment markets branded drugs primarily for central nervous system and endocrine disorders, including RYTARY and CREXONT for Parkinson's disease, and BREKIYA for migraine and cluster headaches. Through AvKARE, Amneal distributes pharmaceuticals and other products to U.S. federal government agencies, as well as retail and institutional markets.

Amneal Pharmaceuticals' primary market is the United States, accounting for approximately 98% of its revenue. The company's headquarters are in Bridgewater, New Jersey, and it has manufacturing plants in New Jersey and New York. Globally, Amneal has expanded its operations with nine facilities in India as of 2023, and it began selling medication in India in October 2022. The company also received approval to launch its first product in China in September 2023 and is slowly expanding through partnerships in Europe and other parts of the world.

Amneal Pharmaceuticals has demonstrated a positive brand reputation in the past year. The company was recognized as the "best company to work for" by BioSpace. Amneal's mission to make medicine accessible for all and its focus on a diversified portfolio of generic and specialty pharmaceuticals contribute to its positive image. The company's strategic collaboration with Metsera for GLP-1s also positions it well in a significant therapeutic category.

Approximately 11.81% of Amneal Pharmaceuticals Inc. stock is held by institutional investors, 40.89% by insiders, and 9.42% by public companies and individual investors. Retail investors hold about 37.88% of the stock. Tushar Bhikhubhai Patel owns the most shares among individual investors. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., Rubric Capital Management LP, and Tpg Gp A, Llc.